Ember LifeSciences Secures $16.5M Series A for Cold Chain Tech

Fundraise Insider tracks newly funded startups each week and delivers verified C-suite contacts straight to your inbox, so you reach the right people while the funding is still fresh. See pricing.

Ember LifeSciences has announced a $16.5 million Series A round led by Sea Court Capital. The financing also drew participation from Cardinal Health, Carrier Ventures, and other investors, including former U.S. Secretary of State Mike Pompeo.

The company is working to reshape how medicine moves around the world, using its proprietary temperature control technology to improve the transport of life-saving medicines and vaccines. Ember LifeSciences started out as an offshoot of Ember Technologies, the design-led temperature control brand behind the award-winning Ember mug, which has passed half a billion dollars in total sales.

The funding will advance the company’s innovation pipeline, including the launch of the Ember Cube 2. That second-generation product builds on lessons from the first Ember Cube, a digital shipping box, and is optimized for greater scale and efficiency so it can extend to broader healthcare networks.

The problem the company is chasing is sizable. The global pharmaceutical cold chain ecosystem loses an estimated $35 billion each year to temperature excursions, and single-use cold chain packaging generates 330 billion pounds of waste annually.